NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where they present peptides to T cells, which gives them a key role in the development of T-cell immune responses. MHC molecules come in two main variants: MHC Class I (MHC-I) and MHC Class II (MHC-II). MHC-I predominantly present peptides derived from intracellular proteins, whereas MHC-II predominantly presents peptides from extracellular proteins. In both cases, the binding between MHC and antigenic peptides is the most selective step in the antigen presentation pathway. Therefore, the prediction of peptide binding to MHC is a powerful utility to predict the possible specificity of a T-cell immune response. Commonly MHC binding prediction tools are trained on binding affinity or mass spectrometry-eluted ligands. Recent studies have however demonstrated how the integration of both data types can boost predictive performances. Inspired by this, we here present NetMHCpan-4.1 and NetMHCIIpan-4.0, two web servers created to predict binding between peptides and MHC-I and MHC-II, respectively. Both methods exploit tailored machine learning strategies to integrate different training data types, resulting in state-of-the-art performance and outperforming their competitors. The servers are available at http://www.cbs.dtu.dk/services/NetMHCpan-4.1/ and http://www.cbs.dtu.dk/services/NetMHCIIpan-4.0/.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among these tools, NetMHCpan stands out in predicting the binding affinity between peptides and MHC-I/II, respectively [139].”
From Single-cell sequencing to multi-omics: technologies and applications (2024) · cites this paper as [139]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470
Self-citationImproved methods for predicting peptide binding affinity to MHC class II molecules
Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan, Z., Sette, A., Peters, B., & Nielsen, M. (2018) · Immunology · doi:10.1111/imm.12889 · Cited by 794
Self-citationAbelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.007 · Cited by 617
Nielsen, M., & Andreatta, M. (2016) · Genome Medicine · doi:10.1186/s13073-016-0288-x · Cited by 517
Self-citationSarkizova, S., Klaeger, S., Le, P. M., Li, L. W., Oliveira, G., Keshishian, H., Hartigan, C. R., Zhang, W., Braun, D. A., Ligon, K. L., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-019-0322-9 · Cited by 499
Reynisson, B., Barra, C., Kaabinejadian, S., Hildebrand, W. H., Peters, B., & Nielsen, M. (2020) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00874 · Cited by 445
Self-citationMHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O'Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 409
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307
Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes
Racle, J., Michaux, J., Rockinger, G. A., Arnaud, M., Bobisse, S., Chong, C., Guillaume, P., Coukos, G., Harari, A., Jandus, C., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0289-6 · Cited by 289
Karosiene, E., Rasmussen, M., Blicher, T., Lund, O., Buus, S., & Nielsen, M. (2013) · Immunogenetics · doi:10.1007/s00251-013-0720-y · Cited by 272
Self-citation
Research works printed but not linked: 1
- O’Donnell T.J., Rubinsteyn A., Bonsack M., Riemer A.B., Laserson U., Hammerbacher J. 2020; MHCFlurry https://github.com/openvax/mhcflurry. 29960884
Cited by
Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal
Ndiaye, M., Lespez, L., Tribolo, C., Rassé, M., Hadjas, I., Davidoux, S., Huysecom, É., & Douze, K. (2024) · Monash University Research Portal (Monash University) · doi:10.3929/ethz-b-000667478 · Cited by 23,868
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
“Most correlative studies of immune protection against SARS-CoV-2 have focused on the induction of neutralizing antibodies (Hotez et al., 2020; Robbiani et al., 2020; Seydoux et al., 2020; Wang et al., 2020).”
BackgroundSelf-citationNeoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858
Tarke, A., Sidney, J., Methot, N., Yu, E. D., Zhang, Y., Dan, J. M., Goodwin, B., Rubiro, P., Sutherland, A., Wang, E., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100355 · Cited by 706
Self-citationTherapeutic cancer vaccines: Advancements, challenges, and prospects
Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01674-3 · Cited by 597
“…for predicting MHC binding af fi nity are trained using data derived from in vivo binding af fi nity measurements or eluting ligands detected by MS. 74 By directly studying ligands eluting from peptide-MHC (pMHC) complexes, predictive models can encompass distinctive characteristics of peptides…”
MethodSARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity
Motozono, C., Toyoda, M., Zahradnik, J., Saito, A., Nasser, H., Tan, T. S., Ngare, I., Kimura, I., Uriu, K., Kosugi, Y., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.06.006 · Cited by 586
Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid Tumors
Leko, V., & Rosenberg, S. A. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.013 · Cited by 449
“This is most commonly done by predicting their ability to bind to specific MHC molecules that are expressed by the cancer, as exemplified by various iterations of the NetMHCpan algorithm (Jurtz et al., 2017; Reynisson et al., 2020).”
BackgroundEfficient evolution of human antibodies from general protein language models
Hie, B. L., Shanker, V. R., Xu, D., Bruun, T. U. J., Weidenbacher, P. A., Tang, S., Wu, W., Pak, J. E., & Kim, P. S. (2024) · Nature Biotechnology · doi:10.1038/s41587-023-01763-2 · Cited by 449
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
Oberhardt, V., Luxenburger, H., Kemming, J., Schulien, I., Ciminski, K., Giese, S., Csernalabics, B., Lang-Meli, J., Janowska, I., Staniek, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03841-4 · Cited by 391
Epigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03520-4 · Cited by 370
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J. E., Cutino-Moguel, T., et al. (2021) · Science · doi:10.1126/science.abh1282 · Cited by 338
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K.-M., Muñoz Sandoval, D., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., et al. (2022) · Science · doi:10.1126/science.abq1841 · Cited by 337
Cancer vaccines: Building a bridge over troubled waters
Sellars, M. C., Wu, C. J., & Fritsch, E. F. (2022) · Cell · doi:10.1016/j.cell.2022.06.035 · Cited by 318
Structured elements drive extensive circular RNA translation
Chen, C.-K., Cheng, R., Demeter, J., Chen, J., Weingarten-Gabbay, S., Jiang, L., Snyder, M. P., Weissman, J. S., Segal, E., Jackson, P. K., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.042 · Cited by 316
Non-viral precision T cell receptor replacement for personalized cell therapy
Foy, S. P., Jacoby, K., Bota, D. A., Hunter, T., Pan, Z., Stawiski, E., Ma, Y., Lu, W., Peng, S., Wang, C. L., et al. (2023) · Nature · doi:10.1038/s41586-022-05531-1 · Cited by 285
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272
Self-citationCancer immune evasion, immunoediting and intratumour heterogeneity
Roerden, M., & Spranger, S. (2025) · Nature Reviews Immunology · doi:10.1038/s41577-024-01111-8 · Cited by 265
Challenges in developing personalized neoantigen cancer vaccines
Katsikis, P. D., Ishii, K. J., & Schliehe, C. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00937-y · Cited by 258
T cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
Naranbhai, V., Nathan, A., Kaseke, C., Berrios, C., Khatri, A., Choi, S., Getz, M. A., Tano-Menka, R., Ofoman, O., Gayton, A., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.029 · Cited by 244
SARS-CoV-2 Epitopes Are Recognized by a Public and Diverse Repertoire of Human T Cell Receptors
Shomuradova, A. S., Vagida, M. S., Sheetikov, S. A., Zornikova, K. V., Kiryukhin, D., Titov, A., Peshkova, I. O., Khmelevskaya, A., Dianov, D. V., Malasheva, M., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.11.004 · Cited by 233
Saini, S. K., Hersby, D. S., Tamhane, T., Povlsen, H. R., Hernandez, S. P. A., Nielsen, M., Gang, A. O., & Hadrup, S. R. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf7550 · Cited by 233
Self-citationSingle-cell sequencing to multi-omics: technologies and applications
Wu, X., Yang, X., Dai, Y., Zhao, Z., Zhu, J., Guo, H., & Yang, R. (2024) · Biomarker Research · doi:10.1186/s40364-024-00643-4 · Cited by 222
“Among these tools, NetMHCpan stands out in predicting the binding affinity between peptides and MHC-I/II, respectively [139].”
MethodMSBooster: improving peptide identification rates using deep learning-based features
Yang, K. L., Yu, F., Teo, G. C., Li, K., Demichev, V., Ralser, M., & Nesvizhskii, A. I. (2023) · Nature Communications · doi:10.1038/s41467-023-40129-9 · Cited by 221
“1/) 62 , they were fi ltered to be between lengths 7 and 12 for Klaeger et al. 57 , or between lengths 8 and 12 for Bassani-Sternberg et al. 65 .”
Tumour mutational burden: clinical utility, challenges and emerging improvements
Budczies, J., Kazdal, D. N., Menzel, M., Beck, S., Kluck, K., Altbürger, C., Schwab, C., Allgäuer, M., Ahadova, A., Kloor, M., et al. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00932-9 · Cited by 218
SARS-CoV-2 antigen exposure history shapes phenotypes and specificity of memory CD8+ T cells
Minervina, A. A., Pogorelyy, M. V., Kirk, A. M., Crawford, J. C., Allen, E. K., Chou, C.-H., Mettelman, R. C., Allison, K. J., Lin, C.-Y., Brice, D. C., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01184-4 · Cited by 212
Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides
Huang, D., Zhu, X., Ye, S., Zhang, J., Liao, J., Zhang, N., Zeng, X., Wang, J., Yang, B., Zhang, Y., et al. (2024) · Nature · doi:10.1038/s41586-023-06834-7 · Cited by 212
Can we predict T cell specificity with digital biology and machine learning?
Hudson, D., Fernandes, R. A., Basham, M., Ogg, G., & Koohy, H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00835-3 · Cited by 206
The Peptide Vaccine of the Future
Nelde, A., Rammensee, H.-G., & Walz, J. S. (2021) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r120.002309 · Cited by 205
“Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.”
BackgroundInfluentialA SARS-CoV-2 vaccine candidate would likely match all currently circulating variants
Dearlove, B., Lewitus, E., Bai, H., Li, Y., Reeves, D. B., Joyce, M. G., Scott, P. T., Amare, M. F., Vasan, S., Michael, N. L., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2008281117 · Cited by 200
Probiotic neoantigen delivery vectors for precision cancer immunotherapy
Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., et al. (2024) · Nature · doi:10.1038/s41586-024-08033-4 · Cited by 198
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
Chu, Y., Zhang, Y., Wang, Q., Zhang, L., Wang, X., Wang, Y., Salahub, D. R., Xu, Q., Wang, J., Jiang, X., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00459-7 · Cited by 187
Structure-based prediction of T cell receptor:peptide-MHC interactions
Bradley, P. (2023) · eLife · doi:10.7554/elife.82813 · Cited by 177
Schmidt, J., Smith, A. R., Magnin, M., Racle, J., Devlin, J. R., Bobisse, S., Cesbron, J., Bonnet, V., Carmona, S. J., Huber, F., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100194 · Cited by 174
SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 + T cell responses
Agerer, B., Koblischke, M., Gudipati, V., Montaño-Gutierrez, L. F., Smyth, M., Popa, A., Genger, J.-W., Endler, L., Florian, D. M., Mühlgrabner, V., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abg6461 · Cited by 172
“To predict the binding strength of WT and mutant peptides, NetMHCpan 4.1 was used ( 30 ).”
InfluentialArtificial intelligence in early drug discovery enabling precision medicine
Boniolo, F., Dorigatti, E., Ohnmacht, A. J., Saur, D., Schubert, B., & Menden, M. P. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2021.1918096 · Cited by 170
Xu, Y., Su, G.-H., Ma, D., Xiao, Y., Shao, Z.-M., & Jiang, Y.-Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00729-7 · Cited by 163
Sandmann, C.-L., Schulz, J. F., Ruiz-Orera, J., Kirchner, M., Ziehm, M., Adami, E., Marczenke, M., Christ, A., Liebe, N., Greiner, J., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.023 · Cited by 163
Reducing Immunogenicity by Design: Approaches to Minimize Immunogenicity of Monoclonal Antibodies
Harris, C. T., & Cohen, S. (2024) · BioDrugs · doi:10.1007/s40259-023-00641-2 · Cited by 162
Huber, F., Arnaud, M., Stevenson, B. J., Michaux, J., Benedetti, F., Thévenet, J., Bobisse, S., Chiffelle, J., Gehert, T., Müller, M., et al. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02420-y · Cited by 163
Development and use of machine learning algorithms in vaccine target selection
Bravi, B. (2024) · npj Vaccines · doi:10.1038/s41541-023-00795-8 · Cited by 163
Association of HLA Class I Genotypes With Severity of Coronavirus Disease-19
Shkurnikov, M. Y., Nersisyan, S. A., Jankevic, T., Galatenko, A. V., Gordeev, I. G., Vechorko, V. I., & Tonevitsky, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.641900 · Cited by 155
Enfield, K. S. S., Colliver, E., Lee, C., Magness, A., Moore, D. A., Sivakumar, M., Grigoriadis, K., Pich, O., Karasaki, T., Hobson, P. S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1380 · Cited by 151
Koh, H. Y., Zheng, Y., Yang, M., Arora, R., Webb, G. I., Pan, S., Li, L., & Church, G. M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00349-8 · Cited by 147
Challenges in neoantigen-directed therapeutics
Lybaert, L., Lefever, S., Fant, B., Smits, E., De Geest, B., Breckpot, K., Dirix, L., Feldman, S. A., van Criekinge, W., Thielemans, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.10.013 · Cited by 142
Next-Generation TB Vaccines: Progress, Challenges, and Prospects
Li, Z., Ye, Z., Li, L., Yang, L., & Gong, W. (2023) · Vaccines · doi:10.3390/vaccines11081304 · Cited by 142
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, C. J., Gibbons, J. M., Pade, C., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Otter, A. D., Joy, G., et al. (2022) · Science · doi:10.1126/science.abm0811 · Cited by 141
Zeng, D., Fang, Y., Qiu, W., Luo, P., Wang, S., Shen, R., Gu, W., Huang, X., Mao, Q., Wang, G., et al. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100910 · Cited by 141
Chiou, S.-H., Tseng, D., Reuben, A., Mallajosyula, V., Molina, I. S., Conley, S., Wilhelmy, J., McSween, A. M., Yang, X., Nishimiya, D., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.014 · Cited by 133
Dey, J., Mahapatra, S. R., Raj, T. K., Kaur, T., Jain, P., Tiwari, A., Patro, S., Misra, N., & Suar, M. (2022) · Gut Pathogens · doi:10.1186/s13099-022-00495-z · Cited by 132
Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics
Carter, P. J., & Quarmby, V. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01051-x · Cited by 133
Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA
Chandran, S. S., Ma, J., Klatt, M. G., Dündar, F., Bandlamudi, C., Razavi, P., Wen, H. Y., Weigelt, B., Zumbo, P., Fu, S. N., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01786-3 · Cited by 130
The pockets guide to HLA class I molecules
Nguyen, A. T., Szeto, C., & Gras, S. (2021) · Biochemical Society Transactions · doi:10.1042/bst20210410 · Cited by 128
Peptide-binding specificity prediction using fine-tuned protein structure prediction networks
Motmaen, A., Dauparas, J., Baek, M., Abedi, M. H., Baker, D., & Bradley, P. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2216697120 · Cited by 124
“We carried out predictions for sets of binding and non-binding peptides from (1, 5, 19) and found that both the PAE, calculated between MHC and peptide, and the per-residue accuracy estimate pLDDT averaged over the peptide residues, provided some discrimination of binders from non-binders (SI Appendix, Fig.”
Expanding the human proteome with microproteins and peptideins
Deutsch, E. W., Kok, L. W., Mudge, J. M., Valls, C., Jungreis, I., Ruiz‐Orera, J., Sun, Z., Kusebauch, U., Fierro-Monti, I., Abelin, J. G., et al. (2026) · Nature · doi:10.1038/s41586-026-10459-x · Cited by 124
Kaabinejadian, S., Barra, C., Alvarez, B., Yari, H., Hildebrand, W. H., & Nielsen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835454 · Cited by 123
Self-citationMachine learning methods and harmonized datasets improve immunogenic neoantigen prediction
Müller, M., Huber, F., Arnaud, M., Kraemer, A. I., Altimiras, E. R., Michaux, J., Taillandier-Coindard, M., Chiffelle, J., Murgues, B., Gehret, T., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.002 · Cited by 120
Gfeller, D., Schmidt, J., Croce, G., Guillaume, P., Bobisse, S., Genolet, R., Queiroz, L., Cesbron, J., Racle, J., & Harari, A. (2023) · Cell Systems · doi:10.1016/j.cels.2022.12.002 · Cited by 117
Xin, L., Qiao, R., Chen, X., Tran, N. H., Pan, S., Rabinoviz, S., Bian, H., He, X., Morse, B., Shan, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30867-7 · Cited by 115
Sequence-to-sequence translation from mass spectra to peptides with a transformer model
Yilmaz, M., Fondrie, W. E., Bittremieux, W., Melendez, C. F., Nelson, R., Ananth, V., Oh, S., & Noble, W. S. (2024) · Nature Communications · doi:10.1038/s41467-024-49731-x · Cited by 114
Evolutionary characterization of lung adenocarcinoma morphology in TRACERx
Karasaki, T., Moore, D. A., Veeriah, S., Naceur-Lombardelli, C., Toncheva, A., Magno, N., Ward, S., Bakir, M. A., Watkins, T. B. K., Grigoriadis, K., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02230-w · Cited by 114
Peptide-Based Vaccines for Tuberculosis
Gong, W., Pan, C., Cheng, P., Wang, J., Zhao, G., & Wu, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.830497 · Cited by 116
Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes
Mayer, R. L., Verbeke, R., Asselman, C., Aernout, I., Gul, A., Eggermont, D., Boucher, K. L., Théry, F., Maia, T. M., Demol, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33721-y · Cited by 112
Sun, S., Liu, L., Zhang, J., Sun, L., Shu, W., Yang, Z., Yao, H., & Zhang, Z. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01732-z · Cited by 112
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Therapeutic high affinity T cell receptor targeting a KRASG12D cancer neoantigen
Poole, A., Karuppiah, V., Hartt, A., Haidar, J. N., Moureau, S., Dobrzycki, T., Hayes, C., Rowley, C., Dias, J., Harper, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32811-1 · Cited by 110
Adoptive Immunotherapy beyond CAR T-Cells
Titov, A., Zmievskaya, E., Ganeeva, I., Valiullina, A., Petukhov, A., Rakhmatullina, A., Рифкатовна, М. Р., Fainshtein, M., Rizvanov, A. A., & Bulatov, E. (2021) · Cancers · doi:10.3390/cancers13040743 · Cited by 110
(2023) · doi:10.1038/s42256-023-00694-6 · Cited by 108
Tambur, A. R., Kosmoliaptsis, V., Claas, F. H. J., Mannon, R. B., Nickerson, P. W., & Naesens, M. (2021) · Kidney International · doi:10.1016/j.kint.2021.06.026 · Cited by 108
Li, J., Xiao, Z., Wang, D., Jia, L., Nie, S., Zeng, X., & Hu, W. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01844-5 · Cited by 105
Integrating multi-omics to unravel host-microbiome interactions in inflammatory bowel disease
Zhang, Y., Thomas, J. P., Korcsmáros, T., & Gul, L. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101738 · Cited by 104
Bukhari, S. N. H., Jain, A., Haq, E., Mehbodniya, A., & Webber, J. L. (2022) · Pathogens · doi:10.3390/pathogens11020146 · Cited by 103
Khetan, R., Curtis, R., Deane, C. M., Hadsund, J. T., Kar, U., Krawczyk, K., Kuroda, D., Robinson, S. A., Sormanni, P., Tsumoto, K., et al. (2022) · mAbs · doi:10.1080/19420862.2021.2020082 · Cited by 103
Multi-epitope vaccines, from design to expression; an in silico approach
Mortazavi, B., Molaei, A., & Fard, N. A. (2024) · Human Immunology · doi:10.1016/j.humimm.2024.110804 · Cited by 103
Goyal, A., Bauer, J., Hey, J., Papageorgiou, D. N., Stepanova, E., Daskalakis, M., Scheid, J., Dubbelaar, M., Klimovich, B., Schwarz, D., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-42417-w · Cited by 102
Design of high-specificity binders for peptide–MHC-I complexes
Liu, B., Greenwood, N. F., Bonzanini, J. E., Motmaen, A., Meyerberg, J., Dao, T., Xiang, X., Ault, R., Sharp, J., Wang, C., et al. (2025) · Science · doi:10.1126/science.adv0185 · Cited by 103
Dey, J., Mahapatra, S. R., Singh, P. K., Prabhuswamimath, S. C., Misra, N., & Suar, M. (2023) · Immunologic Research · doi:10.1007/s12026-023-09374-4 · Cited by 101
Ranking Peptide Binders by Affinity with AlphaFold**
Chang, L., & Perez, A. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202213362 · Cited by 100
Assessing developability early in the discovery process for novel biologics
Fernández-Quintero, M. L., Ljungars, A., Waibl, F., Greiff, V., Andersen, J. T., Gjølberg, T. T., Jenkins, T. P., Voldborg, B. G., Grav, L. M., Kumar, S., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2171248 · Cited by 99
The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
de Silva, T. I., Liu, G., Lindsey, B. B., Dong, D., Moore, S. C., Hsu, S. N., Shah, D. R., Wellington, D., Mentzer, A. J., Angyal, A., et al. (2021) · iScience · doi:10.1016/j.isci.2021.103353 · Cited by 99
Spurr, L. F., Martinez, C. A., Kang, W., Chen, M., Zha, Y., Hseu, R. D., Gutiontov, S. I., Turchan, W. T., Lynch, C. M., Pointer, K. B., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00467-x · Cited by 99
The MHC Motif Atlas: a database of MHC binding specificities and ligands
Tadros, D. M., Eggenschwiler, S., Racle, J., & Gfeller, D. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac965 · Cited by 97
Meynard-Piganeau, B., Feinauer, C., Weigt, M., Walczak, A. M., & Mora, T. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2316401121 · Cited by 92
Next-generation IEDB tools: a platform for epitope prediction and analysis
Yan, Z., Kim, K., Kim, H., Ha, B., Gambiez, A., Bennett, J., Mendes, M. F. D. A., Trevizani, R., Mahita, J., Richardson, E., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae407 · Cited by 91
Self-citationPak, H., Michaux, J., Huber, F., Chong, C., Stevenson, B. J., Müller, M., Coukos, G., & Bassani‐Sternberg, M. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100080 · Cited by 90
Lin, Y., Peng, L., Dong, L., Liu, D., Ma, J., Lin, J., Chen, X., Lin, P., Song, G., Zhang, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1640 · Cited by 90
Designing neoantigen cancer vaccines, trials, and outcomes
Biswas, N., Chakrabarti, S., Padul, V. G., Jones, L. D., & Ashili, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1105420 · Cited by 90
Epitope prediction and identification—Adaptive T cell responses in humans
Sidney, J., Peters, B., & Sette, A. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101418 · Cited by 81
Self-citationAhmed, S. F., Quadeer, A. A., & McKay, M. R. (2022) · Viruses · doi:10.3390/v14010079 · Cited by 89
Villanueva‐Flores, F., Sanchez-Villamil, J. I., & Garcia-Atutxa, I. (2025) · npj Vaccines · doi:10.1038/s41541-025-01258-y · Cited by 89
Guarra, F., & Colombo, G. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.3c00513 · Cited by 87
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
Wang, S. L., & Chan, T. A.-T. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.03.006 · Cited by 87
Ragone, C., Manolio, C., Cavalluzzo, B., Mauriello, A., Tornesello, M. L., Buonaguro, L., Castiglione, F., Vitagliano, L., Iaccarino, E., Ruvo, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002694 · Cited by 86
Cross-protective immunity following coronavirus vaccination and coronavirus infection
Dangi, T., Palacio, N. M., Sanchez, S., Park, M., Class, J., Visvabharathy, L., Ciucci, T., Koralnik, I. J., Richner, J. M., & Penaloza-MacMaster, P. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151969 · Cited by 86
HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection
Augusto, D. G., & Hollenbach, J. A. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102178 · Cited by 85
T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy
Frank, M. L., Lu, K. J., Erdogan, C., Han, Y., HU, J. L., Wang, T., Heymach, J. V., Zhang, J. J., & Reuben, A. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2469 · Cited by 85
Computational immunogenomic approaches to predict response to cancer immunotherapies
Addala, V., Newell, F., Pearson, J. V., Redwood, A., Robinson, B. W. S., Creaney, J., & Waddell, N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00830-6 · Cited by 86
Splicing neoantigen discovery with SNAF reveals shared targets for cancer immunotherapy
Li, G., Mahajan, S., Ma, S., Jeffery, E. D., Zhang, X., Bhattacharjee, A., Venkatasubramanian, M., Weirauch, M. T., Miraldi, E. R., Grimes, H. L., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ade2886 · Cited by 85
Gene fusion neoantigens: Emerging targets for cancer immunotherapy
Wang, Y., Shi, T., Song, X., Liu, B., & Wei, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.02.023 · Cited by 84
Metadata
- Authors
- Reynisson, B., Alvarez, B., Paul, S., Peters, B., & Nielsen, M.
- Affiliations
- Technical University of Denmark (DK)
- National University of General San Martín (AR)
- La Jolla Institute for Immunology (US)
- Corresponding author
- Nielsen, Morten
- Venue
- Nucleic Acids Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-05-14
- Volume
- 48
- Issue
- W1
- Pages
- W449-W454
- ISSN
- 0305-1048 (ISSN-L)
- 1362-4962
- PMC
- PMC7319546
- OpenAlex
- W3024570138
- Cited by
- 2,361
- References
- 26
- Citations by year
- 2026: 493 · 2025: 550 · 2024: 459 · 2023: 345 · 2022: 250 · 2021: 216 · 2020: 47
- FWCI
- 69.61
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Nucleic Acids Research (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Technical University of Denmark, DTU Orbit (Technical University of Denmark, DTU) (submittedVersion, public-domain)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (75N93019C00001)
- EIT Health (19638)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Machine Learning in Bioinformatics
- Keywords
- MHC-peptide binding prediction, MHC class I, MHC class II, antigen presentation, NetMHCpan, machine learning, web server, T cell response
- MeSH terms
- Machine Learning, Histocompatibility Antigens Class II, Ligands, Peptides, Software, Histocompatibility Antigens Class I, Antigen Presentation, Amino Acid Motifs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.